Scinogy, an automated manufacturing systems provider for cell therapies, and Thermo Fisher Scientific will work to develop and commercialize reagent systems to improve the scalability of cell and gene therapy manufacturing.
With Scinogy, Thermo Fisher will provide closed, modular, and automated systems for the development and manufacturing of cell and gene therapy – to be used as an alternative method to the manual processes used in development and clinical trial supply.
Per the partnership agreement, Thermo Fisher will launch its counterflow centrifuge used for closed cell processing in cell and gene therapy manufacturing. According to the company, the Gibco CTS Rotea Counterflow Centrifugation System, is a highly reproducible system for separation, washing, and concentration of autologous and small-scale allogeneic cell therapy samples.
According to Bryan Poltilove, general manager of cell therapy for Thermo Fisher Scientific, this fulfills the market’s need for closed, modular, automated systems, which enable scalable and cost-effective development and manufacturing.
The Rotea can continuously process up to 20L of starting volume to then deliver a concentrate as small as 5ml that contains up to 200m cells per millimeter.
Politilove explained, “This centrifuge provides rapid processing of cells across a wide range of volumes with high levels of precision. By enabling closed manufacturing of cell therapies, it can reduce costs and improve scalability for commercial manufacturing.”
Financial details of the agreement have not been disclosed.
